Top 50 Ai For Genomics in Asia

3BIGS utilizes bio big data and AI-driven platforms to analyze next-generation sequencing (NGS) data, identifying patterns, mutations, and biomarkers for drug discovery and healthcare insights. The company addresses the challenge of extracting actionable information from vast biological datasets, accelerating the development of targeted therapies and improving patient outcomes.

This biotechnology company utilizes artificial intelligence to cultivate and evolve proteins essential for bio-products, enhancing the efficiency of medical research. By providing reliable and rapid access to these proteins, the company addresses the need for improved medical services in the healthcare sector.

Helix integrates genomic data into healthcare systems, enabling health organizations to utilize population genomics for personalized diagnosis, treatment, and prevention. By providing actionable genetic insights, Helix enhances patient outcomes and reduces costs across medical research and clinical care.

The startup develops medical artificial intelligence devices that utilize big data collection, processing, and gene mutation analysis to enhance health management and disease prevention. By enabling real-time analysis of endoscopic images, the technology provides critical insights to medical practitioners, improving treatment strategies and patient outcomes.

Algorithmic Biologics develops a software platform that enhances molecular testing workflows through advanced computational applications, including compression algorithms for next-generation sequencing. This technology significantly reduces library preparation costs by over 60%, making molecular diagnostics more accessible and efficient for healthcare providers.

Engine Biosciences utilizes machine learning and high-throughput biology to identify genetic interactions within complex disease networks, enabling the development of targeted therapeutics and biomarkers for specific patient populations. This approach significantly accelerates the research and development process for new medical therapies, reducing costs and improving clinical outcomes for a range of solid tumors.

The startup develops a bioinformatics platform that employs artificial intelligence to analyze fetal cell-free DNA extracted from maternal blood samples during the first trimester. This technology enables early detection of genetic disorders, including point mutations and chromosomal anomalies, in a non-invasive and cost-effective manner.

MNDL Bio utilizes AI-driven computational models to optimize gene expression for recombinant protein production, significantly enhancing yield and reducing costs. The platform replaces traditional trial-and-error methods with precise, data-driven strain engineering, enabling faster time-to-market and improved sustainability in biotech and foodtech applications.

Great Bay Bio develops biopharmaceuticals using its AI-enabled platforms, AlfaCell and AlfaMedX, which streamline cell line development and optimize cell culture media. This technology reduces the time and complexity of producing high-yield, stable cell lines, addressing inefficiencies in traditional biologics development.

The startup has developed an epigenetics platform that analyzes cancer patients, specifically focusing on Asian cancers, using epigenomic predictive models to generate actionable insights for treatment decisions. This technology enables clinicians to tailor personalized medicine strategies for advanced cancers, improving patient care through data-driven approaches.

Tsingke Biotechnology specializes in synthetic genomics, offering services such as gene synthesis, oligo synthesis, and recombinant protein expression to support research in biotechnology and pharmaceuticals. By providing high-quality, customizable genetic materials and solutions, Tsingke addresses the need for reliable resources in scientific research and drug development.

4baseCare develops precision oncology solutions utilizing next-generation sequencing and comprehensive genomic profiling to identify specific cancer mutations in patients. Their technology addresses the need for personalized treatment options by providing tailored insights that enhance therapeutic decision-making for cancer care in the Indian population.

PrognomiQ develops proprietary multi-omics test products that integrate extensive proteomic, genomic, and metabolomic data to enable early detection and treatment of cancer and complex diseases. By generating high-quality biological insights, the company aims to improve patient outcomes through earlier intervention and more effective therapy monitoring.

Utilizes generative AI to design de novo genes and proteins that integrate multiple biological functions into compact therapeutic molecules. This approach addresses unmet medical needs by enabling the development of highly effective treatments with improved efficiency and specificity.

Igentify Ltd offers a digital platform that streamlines genomic workflows, enabling patients, laboratories, and healthcare providers to access and interpret genetic information securely. This solution addresses the challenge of inefficient genetic data management, enhancing the effectiveness of preventive healthcare services.

Minutia.AI develops probabilistic AI models to simulate the complex interactions within the human gut microbiome, enabling personalized predictions of individual responses to dietary interventions. Their technology addresses the limitations of traditional biomarker approaches by providing granular insights into microbial dynamics and facilitating tailored dietary recommendations for improved health outcomes.

Biomica develops microbiome-based therapeutics using a proprietary computational platform that integrates metagenomics sequencing and AI to identify optimal microbial candidates for treating cancer, immune-mediated, and infectious diseases. The company addresses the challenge of unmet medical needs by maximizing therapeutic efficacy while minimizing adverse effects through carefully curated microbial consortia.

This startup offers whole genome sequencing and genetic testing services to identify health risks and inform personalized medicine. They provide genetic counseling and bioinformatics tools to patients and healthcare providers for accurate genetic analysis.

ConnectingDNA is an AI-powered DNA wellness marketplace that provides personalized, science-backed health recommendations based on user DNA reports. The platform interprets natural language queries to offer tailored guidance across nutrition, fitness, and mental health, connecting users with vetted wellness providers for DNA-informed programs.

Geneyx provides DNA and RNA data analysis and interpretation for whole genome sequencing (WGS), whole exome sequencing (WES), gene panels, and microarrays, enabling rapid transformation of raw genetic data into clinical reports. The platform enhances diagnostic accuracy and efficiency, aiming to eliminate undiagnosed diseases by increasing the diagnostic yield and reducing turnaround times for genetic testing.

bitBiome utilizes single-cell sequencing technology to catalog and evolve microbial genomes, creating a diverse database of over 2 billion sequences. This platform addresses the need for unique enzymes and proteins to enhance biomanufacturing processes across various industries, including drug production and sustainable materials development.

MGI Tech develops genetic sequencers and lab automation tools that enhance genomic analysis and streamline sample preparation processes in life sciences. Their technology addresses the need for efficient, high-throughput sequencing and data management, enabling precise diagnostics and research in healthcare and agriculture.

This startup develops a platform that integrates advanced genomic technologies for diagnostics, prognostics, and therapeutic development. It offers genetic testing and counseling to diagnose and treat rare diseases, enabling personalized care for patients.

AstraGene manufactures in-vitro diagnostic reagents, microbiology media, and molecular biology kits to enhance the accuracy and efficiency of laboratory testing in clinical, food, and veterinary sectors. The company also offers customized AI decision support systems to improve diagnostic processes, serving approximately 150 labs across the UAE and neighboring countries.

The startup develops a genotyping and sequencing platform that translates genetic data into clinical applications, enabling healthcare providers to make informed treatment decisions. This technology enhances patient care and biomedical research by improving the understanding and management of diseases.

Zene is a genome data analysis platform that offers high-precision genomic analysis services using saliva samples to provide individuals with insights into their genetic traits. The platform also supports health insurance organizations by delivering actionable genomic information to reduce medical costs and enhance employee health management.

Foresee Genomics offers an integrated next-generation sequencing (NGS) platform that makes advanced genomic analysis accessible to smaller laboratories. Their solution combines optimized protocols, specialized reagents, and user-friendly bioinformatics tools to reduce costs and lab space requirements. This empowers labs to perform high-accuracy genomic analysis for improved diagnostics and precision medicine.

Vision Medicals specializes in gene technology and precision medicine to enhance patient-specific treatment strategies. The company focuses on utilizing genomic data to improve diagnostic accuracy and tailor therapies for genetic disorders, ultimately increasing treatment efficacy.

Psifas is developing a platform that integrates longitudinal medical records with whole genome sequencing data to facilitate targeted medical research. This approach enables early disease detection and intervention, improving health outcomes by providing researchers with comprehensive, anonymized datasets for analysis.

GenomiCare Biotechnology provides precision cancer medicine services through genomic profiling and targeted therapy recommendations. The company addresses the challenge of ineffective cancer treatments by offering personalized treatment plans based on individual genetic mutations.

Regene Genomics provides predictive diagnostics through genetic testing, enabling individuals to understand their genetic predispositions and make informed health decisions. The company focuses on delivering accurate test results while ensuring data privacy and fostering transparent communication with clients.

This microbiome-based life sciences company develops healthcare solutions using big data analytics, mathematical modeling, deep learning, and AI. Their technology analyzes the human microbiome to provide insights that support individual health and well-being.

The startup has developed an AI-powered drug discovery platform that utilizes data-driven methodologies to enhance traditional drug design processes. By providing scientists in the pharmaceutical industry with user-friendly AI tools, the platform accelerates research timelines and facilitates the development of novel therapeutics, ultimately aiming to reduce the burden of diseases on patients.

Genz develops AI algorithms for genomic data analysis to facilitate personalized treatment plans for women with breast cancer. By leveraging advanced data analytics, the company aims to enhance the precision of therapeutic interventions tailored to individual genetic profiles.

The startup develops genome editing technology that enables the cultivation of bacteria to modify and control microbiomes for therapeutic applications. This approach allows researchers to conduct precise gene editing and microbiome engineering, facilitating the development of targeted treatments for various health conditions.

The startup provides genomic reports tailored for the Indian population by integrating genomic, physiological, and physical data through machine learning algorithms. This approach enables individuals to understand their genetic predispositions and make informed decisions about their diet and lifestyle to mitigate the risk of lifestyle and clinical disorders.

This startup provides an AI-powered blockchain platform for decentralized science, specifically focused on genomics. It offers researchers access to clean, labeled, and organized genetic profiles, accelerating the development of personalized, data-driven medical solutions and reducing time-to-market for genomics-based AI applications.

BiotaX utilizes AI-driven computational biology to construct natural microbial communities tailored for specific functions in health, food, agriculture, and climate applications. The platform addresses the challenge of harnessing the vast diversity of uncultured bacteria to develop effective microbial solutions for various industries.

Genome Co. is a microbiome research and development company that focuses on the discovery and commercialization of novel probiotics and biologics to enhance human health. Their proprietary GNOCLE™ platform enables the identification of microbial strains that can address specific health conditions, thereby improving treatment options in the field of microbiome medicine.

ACT Genomics provides genomic profiling services that deliver actionable insights on biomarkers and genomic alterations to tailor cancer treatment plans for patients. By utilizing precision testing, the company enhances treatment selection and clinical trial matching, improving patient outcomes in oncology.

This startup provides a secure and customizable platform for genomic data analysis, optimizing compute architecture and standardizing bioinformatic algorithms for research, academia, and clinical stakeholders. By simplifying the complexities of genomic data processing, it enhances efficiency and accessibility for users in these fields.

The startup develops novel drugs by leveraging genomic algorithms to analyze naturally occurring cancer resistance mechanisms found in various animals. This approach aims to provide precision therapeutics that mimic effective anti-cancer strategies, addressing the need for more targeted cancer treatments.

This biotechnology company transforms genomic data into actionable insights for healthcare. It leverages GSA Microarray data technology to analyze and interpret genomic information, providing personalized nutrition recommendations and integrated patient management tools.

BathGenBio utilizes artificial intelligence to analyze extensive biobank data, including genomic and clinical information, to identify novel biomarkers and optimize drug discovery processes. The platform addresses the challenges of precision medicine by enhancing target discovery, drug response prediction, and drug repurposing for medical institutions and biotechnology companies.

Clinlab.AI, Inc. provides an AI-powered platform for managing Physician Office Laboratories (POLs), enabling physicians to conduct clinical chemistry, immunology, and genomic testing with precision. This solution addresses the need for efficient lab operations and enhanced clinical decision-making, allowing practices to deliver personalized patient care while minimizing upfront costs.

Amwise Diagnostic specializes in precision medicine technology that utilizes genomic profiling and biomarker analysis to tailor cancer treatment plans for individual patients. This approach enhances treatment efficacy and minimizes adverse effects by ensuring therapies are specifically matched to the unique genetic makeup of each tumor.

GeneCast Biotechnology develops precision cancer diagnostics and companion diagnostics to enhance treatment outcomes for cancer patients. By utilizing genomic profiling and biomarker analysis, the company enables personalized therapy selection, improving the effectiveness of cancer treatments.

The startup has developed an AI-based drug discovery engine that analyzes patient genetic data and disease mutations to identify the most effective medication for individual conditions. By comparing molecular and clinical profiles, the platform enhances treatment precision, ultimately improving patient outcomes and quality of life.

AIGEN Sciences is an AI-driven platform that utilizes machine learning algorithms to accelerate drug discovery and development processes. The platform addresses the lengthy and costly nature of traditional drug research by providing data-driven insights that enhance target identification and compound optimization.

This startup provides a bioinformatics platform that analyzes single-cell genomic data to help researchers understand disease mechanisms. It offers accessible, expert data analysis tools, enabling clients to advance genomic research for personalized medicine.